Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Irinotecan-containing combinations in solid tumors, except colonic carcinomas]

C Couteau1, J P Armand

  • 1Service d'oncologie médicale, hôpital Tenon, Paris, France.

Bulletin Du Cancer
|February 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coupling of single nanodiamonds hosting SiV color centers to plasmonic double bowtie microantennas.

Nanotechnology·2025
Same author

Study of the influence of alcohol on the photostability of four UV filters.

European review for medical and pharmacological sciences·2021
Same author

Soap and syndets: differences and analogies, sources of great confusion.

European review for medical and pharmacological sciences·2020
Same author

Influence of Cosmetic Type and Distribution Channel on the Presence of Regulated Fragrance Allergens: Study of 2044 Commercial Products.

Clinical reviews in allergy & immunology·2020
Same author

Mitigating the photocurrent persistence of single ZnO nanowires for low noise photodetection applications.

Nanotechnology·2018
Same author

Study of the influence of substrate and spectrophotometer characteristics on the in vitro measurement of sunscreens efficiency.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2018

Irinotecan, a topoisomerase I inhibitor, shows antitumor activity. Combinations with cisplatin and etoposide demonstrate synergistic effects, with cisplatin-irinotecan showing promise in lung cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Irinotecan is a novel topoisomerase I inhibitor with demonstrated antitumor activity across various solid tumors.
  • Its unique mechanism allows for combination therapies with other chemotherapeutic agents.

Purpose of the Study:

  • To review published Phase I and II clinical studies of irinotecan.
  • To evaluate the efficacy and toxicity of irinotecan in combination with other drugs, specifically cisplatin and etoposide.

Main Methods:

  • Review of published Phase I and II clinical trials involving irinotecan.
  • Analysis of in vitro and in vivo studies assessing synergistic activity with cisplatin and etoposide.

Main Results:

  • Irinotecan exhibits antitumor activity in solid tumors and squamous cervical carcinoma.

Related Experiment Videos

  • Synergistic activity observed with irinotecan in combination with cisplatin and etoposide.
  • The combination of cisplatin-irinotecan yielded the best results in lung cancer treatment.

    • Conclusions:

    • Irinotecan is a promising agent for solid tumor treatment, particularly in combination therapies.
    • Neutropenia is a dose-limiting toxicity for combination schedules.
    • Cisplatin-irinotecan combination is effective in lung cancer, while optimal scheduling for etoposide-irinotecan requires further determination.